RxSight's Losses Widen Despite Sales Growth, Operating Costs Surge

TL;DR

**RxSight is burning cash faster than it's growing sales, making profitability a distant mirage despite a promising product.**

AI Summary

RxSight, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $29.792 million, up from $21.517 million in the prior year. This 38.46% increase in net loss occurred despite a modest 2.16% rise in sales to $101.871 million from $99.713 million. Gross profit improved to $77.746 million from $70.155 million, but was offset by a substantial 16.49% increase in total operating expenses, which climbed to $114.600 million from $98.385 million. Selling, general and administrative expenses rose to $84.956 million from $73.225 million, and research and development expenses increased to $29.644 million from $25.160 million. The company's cash and cash equivalents increased to $29.633 million as of September 30, 2025, from $16.706 million at December 31, 2024, primarily due to investing activities, including maturities of short-term investments totaling $170.000 million. RxSight anticipates that its current cash, cash equivalents, and short-term investments will be sufficient to fund operations for at least the next 12 months, and does not foresee needing to raise additional capital to reach profitability.

Why It Matters

RxSight's widening net loss, despite revenue growth, signals a critical juncture for investors. The substantial increase in operating expenses, particularly in selling, general, and administrative, suggests aggressive expansion efforts are outstripping sales efficiency. For employees, continued investment in R&D and sales indicates job stability and growth opportunities, but the path to profitability remains distant. Customers benefit from ongoing product development in light adjustable lenses, but the company's financial health could impact long-term support. In a competitive premium intraocular lens market, RxSight's ability to convert market share gains into sustainable profits is paramount, especially as it aims to establish its LAL system as the standard of care.

Risk Assessment

Risk Level: medium — The company's net loss increased by 38.46% to $29.792 million for the nine months ended September 30, 2025, compared to $21.517 million in the prior year. This widening loss, coupled with a 16.49% increase in total operating expenses to $114.600 million, indicates significant cash burn, even though management believes current capital is sufficient for 12 months.

Analyst Insight

Investors should monitor RxSight's operating expense growth closely relative to revenue expansion. While the company projects no need for additional capital to reach profitability, continued widening losses could necessitate future fundraising, potentially diluting existing shareholders. Consider holding if bullish on long-term market penetration, but be wary of short-term volatility due to increasing losses.

Financial Highlights

debt To Equity

0.12

revenue

$101.871M

operating Margin

-36.19%

total Assets

$308.533M

total Debt

$32.563M

net Income

-$29.792M

eps

-$0.73

gross Margin

76.32%

cash Position

$29.633M

revenue Growth

+2.16%

Key Numbers

• $101.871M — Sales (Increased 2.16% for the nine months ended September 30, 2025, compared to $99.713 million in 2024.)
• $29.792M — Net Loss (Increased 38.46% for the nine months ended September 30, 2025, from $21.517 million in 2024.)
• $114.600M — Total Operating Expenses (Increased 16.49% for the nine months ended September 30, 2025, from $98.385 million in 2024.)
• $84.956M — Selling, General and Administrative Expenses (Increased from $73.225 million in 2024 to $84.956 million in 2025.)
• $29.644M — Research and Development Expenses (Increased from $25.160 million in 2024 to $29.644 million in 2025.)
• $29.633M — Cash and Cash Equivalents (Increased from $16.706 million at December 31, 2024, to $29.633 million at September 30, 2025.)
• $0.73 — Basic & Diluted Net Loss Per Share (Increased from $0.56 in 2024 to $0.73 in 2025 for the nine months ended September 30.)
• 41,116,640 — Common Stock Shares Outstanding (As of October 30, 2025, indicating potential dilution from prior periods.)

Key Players & Entities

• RxSight, Inc. (company) — registrant
• U.S. Food and Drug Administration (regulator) — product approval
• Nasdaq Stock Market LLC (company) — exchange for common stock
• RxSight, Limited (company) — wholly owned subsidiary in Hong Kong
• RxSight, B.V. (company) — wholly owned subsidiary in Amsterdam, Netherlands
• RxSight GmbH (company) — wholly owned subsidiary in Germany
• $29.792 million (dollar_amount) — net loss for nine months ended September 30, 2025
• $101.871 million (dollar_amount) — sales for nine months ended September 30, 2025
• $114.600 million (dollar_amount) — total operating expenses for nine months ended September 30, 2025
• $29.633 million (dollar_amount) — cash and cash equivalents as of September 30, 2025

FAQ

Risk Factors

• Increasing Net Loss and Operating Expenses [high — financial]: The company reported a net loss of $29.792 million for the nine months ended September 30, 2025, a 38.46% increase from $21.517 million in the prior year. This widening loss is driven by a substantial 16.49% increase in total operating expenses to $114.600 million, significantly outpacing the modest 2.16% rise in sales to $101.871 million.
• Dependence on Key Personnel and Product Development [medium — operational]: While not explicitly detailed in the provided text, companies in the medical device sector, like RxSight, often face risks related to the loss of key scientific or management personnel. Continued investment in R&D, which increased to $29.644 million from $25.160 million, is crucial for future product innovation and market competitiveness.
• Market Adoption and Competition [medium — market]: The success of RxSight's products depends on market acceptance and adoption by ophthalmologists and patients. The company operates in a competitive landscape, and failure to differentiate its offerings or effectively market them could hinder revenue growth and profitability.
• Regulatory Approval and Compliance [high — regulatory]: As a medical device company, RxSight is subject to stringent regulatory oversight from bodies like the FDA. Delays in obtaining approvals, changes in regulations, or failure to comply with existing standards could significantly impact product launches and market access.
• Cash Burn Rate and Future Funding Needs [medium — financial]: Despite an increase in cash and cash equivalents to $29.633 million, the company's net loss is widening. While management states current cash is sufficient for at least 12 months, a sustained increase in operating expenses without corresponding revenue growth could necessitate future capital raises, potentially diluting existing shareholders.

Industry Context

RxSight operates in the ophthalmic medical device industry, a sector characterized by significant R&D investment and stringent regulatory hurdles. The market is driven by technological innovation aimed at improving vision correction and treating eye diseases. Competition comes from established players and emerging companies offering a range of surgical and non-surgical solutions.

Regulatory Implications

As a medical device manufacturer, RxSight is subject to rigorous FDA regulations for product development, manufacturing, and marketing. Compliance with these regulations is critical for market access and continued operation. Any adverse regulatory actions or changes in the regulatory landscape could materially impact the company's financial performance and prospects.

What Investors Should Do

1. Monitor operating expense growth relative to revenue.
2. Evaluate R&D investment effectiveness.
3. Assess cash runway and potential future financing needs.

Key Dates

• 2025-09-30: End of Nine Months Reporting Period — Key financial results for the period, including increased net loss and operating expenses, were reported.
• 2025-12-31: Previous Year-End — Provided a baseline for comparison of cash and cash equivalents ($16.706 million).

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company has historically incurred more losses than profits, standing at $651.887 million as of September 30, 2025.)

Operating leases right-of-use assets

Assets recognized under accounting standards for leases, representing the right to use an asset for a specified period. (Reflects the company's long-term rental obligations, totaling $10.276 million as of September 30, 2025.)

Additional paid-in capital

The amount of capital investors have paid for stock above its par or stated value. (Represents significant capital raised from equity issuance, totaling $927.756 million as of September 30, 2025.)

Comprehensive loss

Includes net loss plus other gains and losses that are not included in net income, such as unrealized gains or losses on investments. (The company reported a net loss, and the 'Other comprehensive loss' section indicates potential fluctuations in investment values.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, RxSight has experienced a notable increase in its net loss, rising by 38.46% to $29.792 million. This deterioration in profitability occurred despite a modest 2.16% increase in sales, which reached $101.871 million. The primary driver of the wider loss is a significant 16.49% surge in total operating expenses to $114.600 million, encompassing increases in both SG&A and R&D. While gross profit improved, it was insufficient to offset the higher operating costs. The company's cash position has strengthened, but the underlying trend of increasing losses warrants close attention.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share RXST The Nasdaq Stock Mar

Filing Documents

• rxst-20250930.htm (10-Q) — 3227KB
• rxst-ex31_1.htm (EX-31.1) — 31KB
• rxst-ex31_2.htm (EX-31.2) — 31KB
• rxst-ex32_1.htm (EX-32.1) — 15KB
• rxst-ex32_2.htm (EX-32.2) — 15KB
• 0001193125-25-266986.txt ( ) — 11004KB
• rxst-20250930.xsd (EX-101.SCH) — 1466KB
• rxst-20250930_htm.xml (XML) — 1923KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 6 Condensed Consolidated Balance Sheets 6 Condensed Consolidated Statements of Operations and Comprehensive Loss 7 Condensed Consolidated Statements of Equity 8 Condensed Consolidated Statements of Cash Flows 10 Notes to Unaudited Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 35 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 96 Item 3. Defaults Upon Senior Securities 96 Item 4. Mine Safety Disclosures 96 Item 5. Other Information 96 Item 6. Exhibits 98

Signatures

Signatures 99 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS The following discussion and analysis should be read together with our condensed consolidated financial statements and the condensed notes to those statements included elsewhere in this report. This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on our management's beliefs and assumptions and on information currently available to our management. In this report, "we," "us" and "our" refer to RxSight, Inc., a Delaware corporation, and its consolidated subsidiaries.

Forward-looking statements include, but are not limited to, statements concerning the following

Forward-looking statements include, but are not limited to, statements concerning the following: the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements, including our expectation that we do not anticipate the need to raise additional capital or incur additional debt in order to reach profitability from operations, as disclosed in our future Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission ("SEC"), provided that we may opportunistically seek to raise capital under advantageous circumstances from time to time in order to support the expansion of our sales and operations in the U.S. and internationally and to pursue other business opportunities; our belief that our current cash, cash equivalents and short-term investments through the date of filing of this report will be sufficient to fund our operations for at least the next 12 months; our expectation that revenue will increase in absolute dollars as we expand our sales organization and sales territories, add customers, expand the base of doctors that are trained to use our products, and expand awareness of our products with new and existing customers and as doctors perform more procedures using our products; our estimates of expenses, ongoing losses, future revenue, capital requirements and our need for, or ability to obtain, additional financing; our expectations about our gross margins based on the forecast of manufacturing volumes of Light-Adjustable Lenses ("LALs"); our plans for the growth of our business and our organization, including with respect to new geographic markets; our belief that, over time, our adjustable lens solution can be used to address a broad range of cataract surgery patients, including those that would otherwise elect for a conventional cataract procedure today; our belief that our RxSight system offers doctors and patients a significantly m

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) RxSIGHT, INC. CONDENSED CONSOLIDATED BA LANCE SHEETS (In thousands, except share and per share amounts) September 30, December 31, 2025 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 29,633 $ 16,706 Short-term investments 197,883 220,517 Accounts receivable, net 24,151 30,050 Inventories, net 28,950 22,009 Prepaid and other current assets 3,260 4,541 Total current assets 283,877 293,823 Property and equipment, net 13,096 12,413 Operating leases right-of-use assets 10,276 11,217 Restricted cash 748 750 Other assets 536 360 Total assets $ 308,533 $ 318,563 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,377 $ 4,544 Accrued expenses and other current liabilities 17,621 20,358 Lease liabilities 1,293 974 Total current liabilities 22,291 25,876 Long-term lease liabilities 10,272 11,322 Other long-term liabilities — 127 Total liabilities 32,563 37,325 Commitments and contingencies (Note 8) Stockholders' equity: Common stock, $ 0.001 par value, 900,000,000 shares authorized, 41,081,550 shares issued and outstanding as of September 30, 2025 and 40,428,220 shares issued and outstanding as of December 31, 2024 41 40 Preferred stock, $ 0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding — — Additional paid-in capital 927,756 903,127 Accumulated other comprehensive income 60 166 Accumulated deficit ( 651,887 ) ( 622,095 ) Total stockholders' equity 275,970 281,238 Total liabilities and stockholders' equity $ 308,533 $ 318,563 See accompanying notes to unaudited condensed consolidated financial statements. 6 RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMEN TS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (In thousands, except share and per share amounts

View Full Filing

View this 10-Q filing on SEC EDGAR